Rachel Sachs, JD, MPH, is an Associate Professor of Law at Washington University in St. Louis, where her work explores the interaction of intellectual property law, food and drug regulation, and health law. Professor Sachs’ scholarship has appeared in legal journals that include the Harvard Journal of Law & Technology, the University of California-Davis Law Review, the Yale Journal of Law & Technology, and the peer-reviewed Journal of Law and the Biosciences, and medical journals that include the New England Journal of Medicine and the Annals of Internal Medicine.
Prior to joining the Washington University faculty, Professor Sachs was an Academic Fellow at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics and a Lecturer in Law at Harvard Law School. She also clerked for the Hon. Richard A. Posner of the U.S. Court of Appeals for the Seventh Circuit.
Sachs received her J.D. magna cum laude from Harvard Law School and a Master of Public Health from the Harvard School of Public Health. She received her A.B. in Bioethics from Princeton University.
Recent Posts by Rachel Sachs
On Monday, the House of Representatives released the latest version of the proposed Food and Drug Administration user fee reauthorization bill. The House is expected to vote on the must-pass bill as early as today, but the Senate has not yet set forth its own timeline for voting on the bill.
July 12, 2017 | Drugs and Medical Innovation
On Tuesday, June 13, the Senate HELP Committee held the first of three planned hearings on high drug prices. One of the most important points to come out of the hearing was that there is bipartisan concern about high drug prices, even if there is as yet little agreement on what to do about them.
On May 11, the Senate Committee on Health, Education, Labor and Pensions marked up the proposed FDA user fee reauthorization bill and voted 21-2 to advance it to the full Senate. The bill would reauthorize the fee system for FDA approval of drugs, medical devices, generic drugs, and biosimilars.
May 15, 2017 | Drugs and Medical Innovation
A bipartisan consensus has emerged that something must be done to tackle drug prices. There’s less consensus about what that something ought to be. One alternative, “value-based pricing,” may hold promise.
In a presidential administration whose confirmation hearings have sparked more than a few contentious moments, FDA Commissioner-designate Scott Gottlieb’s confirmation hearing was remarkable for how unremarkable it was. But to say the hearing was uneventful is not to say that it was uninteresting.
April 7, 2017 | Drugs and Medical Innovation
A Symposium On Health Law. Just 32 states including DC have expanded Medicaid pursuant to the ACA. Some have successfully negotiated customized expansions with CMS through Section 1115 waivers, seeking to expand Medicaid only on their terms. However, this new set of waivers should give us pause.
Chief Justice Roberts offered two reasons for declining to defer to the IRS’ interpretation of the ACA. But I want to focus on what these two aspects of the Chief Justice’s logic may mean for health law in particular.
Editor’s note: This post is part of a series stemming from the Third Annual Health Law Year in P/Review event held at Harvard Law School on Friday, January 30, 2015. The conference brought together leading experts to review major developments in health law over the previous year, and preview...
April 10, 2015 | Drugs and Medical Technology